ATE189526T1 - METHOD FOR DETECTING ACTIVE DOMAIN AND AMINO ACID RESIDUE IN POLYPEPTIDES AND HORMONE VARIANTS - Google Patents

METHOD FOR DETECTING ACTIVE DOMAIN AND AMINO ACID RESIDUE IN POLYPEPTIDES AND HORMONE VARIANTS

Info

Publication number
ATE189526T1
ATE189526T1 AT89912824T AT89912824T ATE189526T1 AT E189526 T1 ATE189526 T1 AT E189526T1 AT 89912824 T AT89912824 T AT 89912824T AT 89912824 T AT89912824 T AT 89912824T AT E189526 T1 ATE189526 T1 AT E189526T1
Authority
AT
Austria
Prior art keywords
polypeptide
amino acid
polypeptides
substituted
active domain
Prior art date
Application number
AT89912824T
Other languages
German (de)
Inventor
James A Wells
Brian C Cunningham
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE189526T1 publication Critical patent/ATE189526T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

The invention provides methods for the systematic analysis of the structure and function of polypeptides by identifying active domains which influence the activity of the polypeptide with a target substance. Such active domains are determined by substituting selected amino acid segments of the polypeptide with an analogous polypeptide segment from an analog to the polypeptide. The analog has a different activity with the target substance as compared to the parent polypeptide. The activities of the segment-substituted polypeptides are compared to the same activity for the parent polypeptide for the target. A comparison of such activities provides an indication of the location of the active domain in the parent polypeptide. The invention also provides methods for identifying the active amino acid residues within the active domain of the parent polypeptide. The method comprises substituting a scanning amino acid for one of the amino acid residues within the active domain of the parent polypeptide and assaying the residue-substituted polypeptide so formed with a target substance. The invention further provides polypeptide variants comprising segment-substituted and residue-substituted growth hormones, prolactins and placental lactogens.
AT89912824T 1988-10-28 1989-10-30 METHOD FOR DETECTING ACTIVE DOMAIN AND AMINO ACID RESIDUE IN POLYPEPTIDES AND HORMONE VARIANTS ATE189526T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26461188A 1988-10-28 1988-10-28
US42806689A 1989-10-26 1989-10-26
PCT/US1989/004778 WO1990004788A1 (en) 1988-10-28 1989-10-30 Method for identifying active domains and amino acid residues in polypeptides and hormone variants

Publications (1)

Publication Number Publication Date
ATE189526T1 true ATE189526T1 (en) 2000-02-15

Family

ID=26950658

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89912824T ATE189526T1 (en) 1988-10-28 1989-10-30 METHOD FOR DETECTING ACTIVE DOMAIN AND AMINO ACID RESIDUE IN POLYPEPTIDES AND HORMONE VARIANTS

Country Status (6)

Country Link
US (4) US5580723A (en)
EP (1) EP0397834B1 (en)
AT (1) ATE189526T1 (en)
CA (2) CA2001774C (en)
DE (1) DE68929151T2 (en)
WO (1) WO1990004788A1 (en)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
ATE189526T1 (en) * 1988-10-28 2000-02-15 Genentech Inc METHOD FOR DETECTING ACTIVE DOMAIN AND AMINO ACID RESIDUE IN POLYPEPTIDES AND HORMONE VARIANTS
US6583115B1 (en) * 1989-10-12 2003-06-24 Ohio University/Edison Biotechnology Institute Methods for treating acromegaly and giantism with growth hormone antagonists
WO1992003478A1 (en) * 1990-08-17 1992-03-05 Genentech, Inc. Metal ion mediated receptor binding of polypeptide hormones
NZ240718A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin analogues carrying mutations in the alpha-helix-1 region
US5310882A (en) * 1990-11-30 1994-05-10 American Cyanamid Company Somatotropins with alterations in the α-helix 3 region
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
DK0564531T3 (en) * 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
US5510459A (en) * 1991-01-17 1996-04-23 Zymogenetics, Inc. Glucagon antagonists
ES2085004T3 (en) * 1991-01-17 1996-05-16 Zymogenetics Inc METHODS TO DETECT GLUCAGON ANTAGONISTS.
DE69231467T2 (en) * 1991-05-10 2001-01-25 Genentech Inc SELECTION OF AGONISTS AND ANTAGONISTS OF LIGANDS
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
US5763584A (en) * 1992-05-18 1998-06-09 Genentech, Inc. Receptor activation with hepatocyte growth factor agonists
WO1993023550A2 (en) * 1992-05-18 1993-11-25 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
SG54115A1 (en) 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
US5849535A (en) * 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
IT1261787B (en) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio METHODOLOGY FOR THE SELECTION OF SUPERAGONISTS, ANTAGONISTS AND SUPER-ANTAGONISTS OF HORMONES OF WHICH RECEPTOR COMPLEX IS PART OF GP 130.
US6335319B1 (en) * 1994-11-15 2002-01-01 Metabolic Pharmaceuticals, Inc. Treatment of obesity
US6475806B1 (en) 1995-06-07 2002-11-05 Praecis Pharmaceuticals, Inc. Anchor libraries and identification of peptide binding sequences
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6238915B1 (en) * 1996-02-13 2001-05-29 Jcr Pharmaceuticals Co., Ltd. Mutant human growth hormones and their uses
SE9601231D0 (en) * 1996-03-29 1996-03-29 Pharmacia Ab Monoclonal antibody
US5945296A (en) * 1996-03-29 1999-08-31 Pharmacia & Upjohn Ab Monoclonal antibody
US6500660B1 (en) * 1996-11-27 2002-12-31 Université Catholique de Louvain Chimeric target molecules having a regulatable activity
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7365166B2 (en) * 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
EP1695985B1 (en) * 1997-04-07 2011-03-09 Genentech, Inc. Methods for forming humanised antibodies by random mutagenesis
DE122005000026I1 (en) * 1997-04-07 2005-08-04 Genentech Inc Anti-VEGF antibodies.
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
GB2375765B (en) * 1997-11-14 2003-02-26 Kymed Gb Ltd Tagged growth hormone molecules
GB9723955D0 (en) * 1997-11-14 1998-01-07 Generic Biolog Limited Improvements in or relating to detection of molecules in samples
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
EP1100890A2 (en) 1998-07-27 2001-05-23 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
WO2000023610A1 (en) 1998-10-21 2000-04-27 Chugai Seiyaku Kabushiki Kaisha Method for screening compound inhibiting signal transduction of inflammatory cytokine
EP1141017B1 (en) 1998-12-30 2008-09-10 Beth Israel Deaconess Medical Center, Inc. Characterization of the soc/crac calcium channel protein family
US7063959B1 (en) 1998-12-30 2006-06-20 Beth Israel Deaconess Medical Center, Inc. Compositions of the SOC/CRAC calcium channel protein family
US20040005673A1 (en) 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
AU774306B2 (en) * 1999-01-05 2004-06-24 Trustees Of Boston University Improved nucleic acid cloning
US8153400B1 (en) 1999-04-26 2012-04-10 Beth Israel Deaconess Medical Center, Inc. Nucleic acids encoding a mutT domain-containing polypeptide
US6946265B1 (en) * 1999-05-12 2005-09-20 Xencor, Inc. Nucleic acids and proteins with growth hormone activity
US7166573B1 (en) * 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
WO2001000874A2 (en) 1999-06-30 2001-01-04 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
AT408721B (en) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIG
US20030180714A1 (en) * 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
SE0000837D0 (en) 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
DE10016083A1 (en) * 2000-03-31 2001-10-18 Ingenium Pharmaceuticals Ag Non-human animal model for growth deficiency and defects in information processing or cognitive function and its use
US20020032154A1 (en) * 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
US7435562B2 (en) * 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
AU2001277014A1 (en) * 2000-07-21 2002-02-05 Trustees Of Boston University Modular vector systems
JP4520631B2 (en) * 2000-11-22 2010-08-11 松本油脂製薬株式会社 Durable water permeability-imparting agent and its fiber
US7271150B2 (en) 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP3993560B2 (en) * 2001-08-30 2007-10-17 ステム セル セラピューティクス インコーポレイテッド Neural stem cell differentiation and therapeutic applications
AU2002325711C1 (en) * 2001-09-14 2008-05-29 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
EP1430113A2 (en) * 2001-09-18 2004-06-23 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
ES2500918T3 (en) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Albumin and interferon beta fusion proteins
JP4514606B2 (en) 2002-05-09 2010-07-28 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド IL1RL-1 as a cardiovascular disease marker and therapeutic target
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
EP2095823A1 (en) 2002-07-30 2009-09-02 Stem Cell Therapeutics Inc. GM-CSF for treating demyelination
CA2492442A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
ATE537186T1 (en) 2002-10-07 2011-12-15 Ludwig Inst For Cancer Res Ltd P53 BINDING POLYPEPTIDE
CA2510003A1 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20050239082A1 (en) * 2003-01-22 2005-10-27 Temple Smith Alien sequences
US7396646B2 (en) * 2003-01-22 2008-07-08 Modular Genetics, Inc. Alien sequences
ATE534730T1 (en) 2003-02-11 2011-12-15 Shire Human Genetic Therapies DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DISEASES AND OTHERS USING AN ENZYME THAT PRODUCES FORMYLGLYCIN
AU2004248187A1 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
WO2005012531A2 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
AU2005206885B2 (en) 2004-01-14 2012-02-02 Ohio University Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
ATE550041T1 (en) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag TRANSGLUTAMINASE-MEDIATED CONJUGATION OF PEPTIDES
WO2005074524A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
ATE556716T1 (en) * 2004-02-13 2012-05-15 Stem Cell Therapeutics Corp USE OF LUTEINIZING HORMONE (LH) AND CHORIONIC GONADOTROPHIN (HCG) FOR NEURAL STEM CELL PROLIFERATION AND NEUROGENesis
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP1735336A2 (en) * 2004-04-16 2006-12-27 Genentech, Inc. Omi pdz modulators
WO2005110015A2 (en) 2004-04-19 2005-11-24 Ohio University Cross-linkable glycoproteins and methods of making the same
EP1789453A2 (en) * 2004-05-18 2007-05-30 Genentech, Inc. M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
AU2004320986A1 (en) * 2004-06-23 2006-01-05 Usv Limited Chimeric human growth hormone derived from the placenta and pituitary isoform and processes for obtaining said chimera
CA2569381A1 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US8197817B2 (en) 2004-12-17 2012-06-12 Dana-Farber Cancer Institute, Inc. Regulation of mink in thymocytes and T lymphocytes
CA2590462C (en) 2004-12-22 2017-02-28 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
EP2284191A3 (en) * 2004-12-22 2011-07-20 Ambrx, Inc. Process for the preparation of hGH
BRPI0519170A8 (en) * 2004-12-22 2018-05-08 Ambrx Inc human growth hormone formulations comprising an unnaturally encoded amino acid
US7736872B2 (en) * 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
CN101247821B (en) * 2005-06-03 2013-01-23 Ambrx公司 Improved human interferon molecules and their uses
US7632823B2 (en) * 2005-08-18 2009-12-15 Ambrx, Inc. Compositions of tRNA and uses thereof
WO2007036033A1 (en) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
ATE456798T1 (en) 2005-10-12 2010-02-15 Allergan Inc TESTING OF MOLECULAR OR SUB-CELLULAR INTERACTIVITY USING DEPOLARIZATION AFTER RESONANCE ENERGY TRANSFER (DARET)
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
JP5508716B2 (en) * 2005-11-08 2014-06-04 アンブルックス，インコーポレイテッド Accelerators for modifying unnatural amino acids and unnatural amino acid polypeptides
KR20080079643A (en) * 2005-11-16 2008-09-01 암브룩스, 인코포레이티드 Methods and compositions comprising non-natural amino acids
US8957187B2 (en) 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
EP1968635B1 (en) * 2005-12-14 2014-09-17 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
KR20080103108A (en) * 2006-03-17 2008-11-26 스템 셀 테라퓨틱스 코포레이션 Dosing regimes for lh or hcg and epo for treatment of neurological disorders
EP2002259B1 (en) 2006-04-10 2012-05-16 Genentech, Inc. Disheveled PDZ modulators
EP2016101A2 (en) * 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
DK2044111T3 (en) 2006-06-21 2014-11-17 Musc Found For Res Dev OBJECTIVE TO COMPLEMENT FACTOR H FOR TREATMENT OF DISEASES
MX2009002523A (en) * 2006-09-08 2009-03-20 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their uses.
CA2662753C (en) * 2006-09-08 2016-02-23 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
WO2008030614A2 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
TW200823234A (en) * 2006-10-03 2008-06-01 Novo Nordisk As Peptides with high affinity for the prolactin receptor
EP3926045A1 (en) 2007-03-22 2021-12-22 Heptares Therapeutics Limited Mutant proteins and methods for selecting them
ATE554785T1 (en) 2007-03-30 2012-05-15 Ambrx Inc MODIFIED FGF-21 POLYPEPTIDES AND THEIR USE
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2008143666A2 (en) * 2007-05-17 2008-11-27 Genentech, Inc. Crystal structures of neuropilin fragments and neuropilin-antibody complexes
KR101656107B1 (en) 2007-11-20 2016-09-08 암브룩스, 인코포레이티드 Modified insulin polypeptides and their uses
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
MX344166B (en) 2008-02-08 2016-12-07 Ambrx Inc Modified leptin polypeptides and their uses.
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
NZ600382A (en) * 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
CA2733200A1 (en) 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
EP3216800A1 (en) 2008-09-26 2017-09-13 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
NZ607477A (en) 2008-09-26 2014-09-26 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
MX2011007736A (en) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Stable growth hormone compounds.
EP2417163B1 (en) 2009-04-10 2019-02-27 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
HUE035773T2 (en) 2009-06-05 2018-05-28 Ablynx Nv Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
CN102612376A (en) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 Growth hormones with prolonged in-vivo efficacy
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
CN107674121A (en) 2009-12-21 2018-02-09 Ambrx 公司 Bovine somatotropin polypeptide and its purposes by modification
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
JP5875527B2 (en) 2010-01-22 2016-03-02 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone with extended efficacy in-vivo
CA2787895A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
EP2595661A1 (en) 2010-07-22 2013-05-29 Novo Nordisk Health Care AG Growth hormone conjugates
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CA2850514A1 (en) 2011-10-14 2013-04-18 Genentech, Inc. Peptide inhibitors of bace1
BR112014008863A2 (en) 2011-10-14 2019-08-20 Genentech Inc isolated zimogene activating peptide (zap), zap fusion, methods
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
JP2016523241A (en) 2013-06-14 2016-08-08 プレジデント アンド フェローズ オブ ハーバード カレッジ Stabilized polypeptide insulin receptor modulators
SI3412302T1 (en) 2014-10-24 2021-09-30 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
EP3964522A1 (en) * 2015-11-16 2022-03-09 Ubiprotein, Corp. A method for extending half-life of a protein
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development Compositions and methods for treating central nervous system injury
AU2018219283B2 (en) 2017-02-08 2022-05-19 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670393A (en) * 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
US4665160A (en) 1982-03-22 1987-05-12 Genentech, Inc. Novel human growth hormone like protein HGH-V encoded in the human genome
US4699897A (en) * 1983-06-04 1987-10-13 Amgen Biologically active peptides structurally related to regions within growth hormones
BG49718A3 (en) 1983-07-15 1992-01-15 Bio Technology General Corp Method for preparing of polypeptid with superoxiddismutasne activitty
US4888286A (en) * 1984-02-06 1989-12-19 Creative Biomolecules, Inc. Production of gene and protein analogs through synthetic gene design using double stranded synthetic oligonucleotides
US4732973A (en) * 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
US4665180A (en) * 1984-11-06 1987-05-12 Petrolite Corporation Substituted tetrahydropyrimidines and octahydrophenanthridines
US4655160A (en) * 1985-09-10 1987-04-07 David R. Ligh Deck box
JPH01502640A (en) * 1987-03-12 1989-09-14 アムジエン・インコーポレーテツド bovine growth hormone analog
DE3877300T2 (en) * 1987-04-02 1993-06-03 Genentech Inc SUBSTRATE SUPPORTED CATALYSIS.
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
ATE189526T1 (en) * 1988-10-28 2000-02-15 Genentech Inc METHOD FOR DETECTING ACTIVE DOMAIN AND AMINO ACID RESIDUE IN POLYPEPTIDES AND HORMONE VARIANTS
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6238915B1 (en) 1996-02-13 2001-05-29 Jcr Pharmaceuticals Co., Ltd. Mutant human growth hormones and their uses

Also Published As

Publication number Publication date
US6451561B1 (en) 2002-09-17
CA2001774C (en) 2001-10-16
EP0397834A4 (en) 1992-10-28
US5580723A (en) 1996-12-03
US5955346A (en) 1999-09-21
DE68929151T2 (en) 2000-07-20
CA2345497A1 (en) 1990-04-28
EP0397834B1 (en) 2000-02-02
DE68929151D1 (en) 2000-03-09
WO1990004788A1 (en) 1990-05-03
EP0397834A1 (en) 1990-11-22
CA2001774A1 (en) 1990-04-28
US6428954B1 (en) 2002-08-06

Similar Documents

Publication Publication Date Title
ATE189526T1 (en) METHOD FOR DETECTING ACTIVE DOMAIN AND AMINO ACID RESIDUE IN POLYPEPTIDES AND HORMONE VARIANTS
Schally et al. The amino acid sequence of a peptide with growth hormone-releasing activity isolated from porcine hypothalamus
Hofmann et al. An approach to the targeted attachment of peptides and proteins to solid supports.
LU91015I2 (en) Recombinate (Rurioctocog alfa) in all its forms covered by the basic patent
Tregear et al. Solid-Phase Synthesis of the Biologically Active N-Terminal 1—34 Peptide of Human Parathyroid Hormone
DE68905633T2 (en) T CELL ACTIVATION MARKER.
Eipper et al. Amidation of joining peptide, a major pro-ACTH/endorphin-derived product peptide.
ES2090598T3 (en) LIGANDO-MEDIATED IMMUNO-FUNCTIONAL HORMONE UNION PROTEIN TEST PROCEDURE.
Sexton et al. Biologically active salmon calcitonin-like peptide is present in rat brain
Habener et al. Bovine proparathyroid hormone: structural analysis of radioactive peptides formed by limited cleavage
Goltzman et al. Metabolism and biological activity of parathyroid hormone in renal cortical membranes.
KR950700934A (en) Method for inhibiting proliferation of T cells using a peptide fragment of myelin basic protein
Schwyzer Synthetische polypeptide mit physiologischer wirkung
Tang et al. Age-related and diurnal changes in Met5-Enk-Arg6-Phe7 and Met5-enkephalin contents of pituitary and rat brain structures
ES2150495T3 (en) FLT3 LEAGUES PURIFIED FROM MAMMAL AND AGONISTS AND ANTAGONISTS THEREOF.
Goltzman et al. Conversion of proparathyroid hormone to parathyroid hormone: studies in vitro with trypsin
BULANT et al. Processing of thyrotropin-releasing hormone (TRH) prohormone in the rat olfactory bulb generates novel TRH-related peptides
Vestling Insulin: HPLC mapping of protease digestion products: A biochemistry laboratory experiment
DE69131289D1 (en) POLYPEPTIDES WITH AN ACTIVITY OF THE HUMAN DOPAMINERGIC RECEPTOR, THEIR ENCODING NUCLEIC ACID SEQUENCES AND USE OF THESE POLYPEPTIDES
Vance et al. Additive Edman degradation to sequence small peptides
Nakagawa et al. Retro analogs related to oxytocin
Lewis Chemistry of prolactin
IT1242173B (en) HIGHLY SENSITIVE QUANTITATIVE ANALYSIS METHOD OF BILE ACIDS AND COMPOSITION FOR THE QUANTITATIVE ANALYSIS.
DE3783840D1 (en) METHOD FOR DETERMINING PLASMA PROTEIN AND TEST SET THEREFOR.
Hohenwarter et al. Analysis of mitogenic activity of proteins after separation by gel electrophoresis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time